Rankings
▼
Calendar
MESO FY 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena
MESO
Mesoblast Limited
$2B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
-76.8% YoY
Gross Profit
-$78M
-1049.8% margin
Operating Income
-$109M
-1463.2% margin
Net Income
-$99M
-1325.3% margin
EPS (Diluted)
$-1.60
Cash Flow
Operating Cash Flow
-$107M
Free Cash Flow
-$108M
Stock-Based Comp.
$13M
Balance Sheet
Total Assets
$745M
Total Liabilities
$163M
Stockholders' Equity
$581M
Cash & Equivalents
$137M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$7M
$32M
-76.8%
Gross Profit
-$78M
-$49M
-58.6%
Operating Income
-$109M
-$75M
-45.7%
Net Income
-$99M
-$78M
-26.8%
← Q4 2020
All Quarters
Q1 2021 →